Lina B A R, Bär A
TNO Nutrition and Food Research, P.O. Box 360, 3700 AJ Zeist, The Netherlands.
Regul Toxicol Pharmacol. 2004 Jun;39 Suppl 1:S14-26. doi: 10.1016/j.yrtph.2004.05.006.
The toxicity of alpha-cyclodextrin (alpha-CD), a cyclic polymer of six alpha-1,4-linked glucopyranosyl units with potential applications as a food ingredient, more specifically a water-soluble dietary fiber, was examined in a 4-week range finding study and a 13-week oral toxicity study in rats. In the 4-week study, the test substance was administered to groups of Bor:WISW(SPF;Cpb) rats at dietary levels of 0, 1, 5, and 15% (5 rats/sex/group). An additional group received a diet with 5% beta-CD. In the 13-week study, groups of Crl:(WI)WU Br rats received diets with 0, 1.5, 5, or 20% alpha-CD. An additional group received a diet with 20% lactose (20 rats/sex/group). Satellite groups of 10 rats/sex were attached to the control, 20% alpha-CD and 20% lactose group. Following the 13-week treatment period, these satellite groups were kept on a standard, cereal-based rodent diet for a 4-week recovery period. Parameters measured during the two studies included clinical signs, body weights, food and water intake, hematological and clinicochemical parameters, and organ weights as well as gross and histopathological observations at necropsy. In the 13-week study, ophthalmoscopic examinations as well as urine and feces analyses were also conducted. There were no treatment-related mortalities in either study. In the 4-week study, persistent diarrhea was the most prominent, treatment-related effect observed in the animals of the 15% alpha-CD group especially in the male animals. In association with this effect, food consumption and food conversion efficiency were decreased. In line with observations from studies with other low-digestible, yet fermentable carbohydrates, the weight of the full and empty cecum was increased significantly in the 5% alpha-CD, 5% beta-CD, and 15% alpha-CD group. The reduced relative liver weights (in males and females) and the significantly increased relative testes weight which were observed in the 15% alpha-CD group, were attributed to the impaired nutritional condition (due to diarrhea) and the reduced body weight of the animals of this group, respectively. Microscopic examination of the main organs did not reveal pathological alterations that could be attributed to the alpha-CD treatment. In the 13-week study, soft stool and infrequent mild diarrhea were observed only during the first 2-3 weeks in the 20% alpha-CD and 20% lactose group (mainly male animals). Accordingly, body weights were reduced in males of the 20% lactose group throughout the study and in the 20% alpha-CD group during the last week of the study. Food intakes were slightly increased in the 20% alpha-CD group and the food conversion efficiency, was significantly reduced in males, but not females, of the 20% alpha-CD and 20% lactose group. There were no treatment-related changes of hematological parameters. In line with similar observations from studies on other low-digestible carbohydrates, the urinary pH was decreased and urinary calcium levels increased in the 20% alpha-CD and 20% lactose group. Similarly, the fecal dry weight and nitrogen output was increased in these groups. At termination of the treatment, significantly in creased cecum weights (full and empty) were observed in the 5 and 20% alpha-CD groups and the 20% lactose group. The relative (not absolute) weight of the spleen was significantly increased in males of the 20% alpha-CD group. In the 20% lactose group, the relative weights of the spleen and liver (females) and the testes, brain, and adrenals (males) were significantly increased. The histopathological examination of these and all other organs and tissues did not reveal any abnormalities that could be attributed to the alpha-CD or lactose treatment. In conclusion, the ingestion of alpha-CD for 13-weeks at dietary levels of up to 20% (corresponding to intakes of 12.6 and 13.9 g/kg bodyweight/d in male and female rats, respectively) did not produce any signs of toxicity or adverse effects.
α-环糊精(α-CD)是一种由六个α-1,4-连接的吡喃葡萄糖基单元组成的环状聚合物,具有作为食品成分的潜在应用,更具体地说是一种水溶性膳食纤维。在一项为期4周的范围查找研究和一项为期13周的大鼠口服毒性研究中,对其毒性进行了检测。在4周的研究中,将受试物质以0%、1%、5%和15%的膳食水平给予Bor:WISW(SPF;Cpb)大鼠组(每组5只/性别)。另外一组给予含5%β-环糊精的饲料。在13周的研究中,Crl:(WI)WU Br大鼠组接受含0%、1.5%、5%或20%α-环糊精的饲料。另外一组给予含20%乳糖的饲料(每组20只/性别)。每组10只/性别的卫星组与对照组、20%α-环糊精组和20%乳糖组相连。在为期13周的治疗期后,这些卫星组在标准的谷物类啮齿动物饲料上维持4周的恢复期。两项研究期间测量的参数包括临床体征、体重、食物和水摄入量、血液学和临床化学参数、器官重量以及尸检时的大体和组织病理学观察。在13周的研究中,还进行了眼科检查以及尿液和粪便分析。两项研究中均未出现与治疗相关的死亡。在4周的研究中,持续性腹泻是在15%α-环糊精组动物中观察到的最突出的与治疗相关的效应,尤其是在雄性动物中。与此效应相关,食物消耗和食物转化效率降低。与其他低消化性但可发酵碳水化合物的研究观察结果一致,在5%α-环糊精、5%β-环糊精和15%α-环糊精组中,充满和排空的盲肠重量显著增加。在15%α-环糊精组中观察到的相对肝脏重量降低(雄性和雌性)以及相对睾丸重量显著增加,分别归因于该组动物营养状况受损(由于腹泻)和体重降低。主要器官的显微镜检查未发现可归因于α-环糊精治疗的病理改变。在13周的研究中,仅在20%α-环糊精和20%乳糖组的前2 - 3周观察到软便和偶尔的轻度腹泻(主要是雄性动物)。因此,在整个研究期间,20%乳糖组雄性动物的体重降低,在研究的最后一周,20%α-环糊精组雄性动物的体重降低。20%α-环糊精组的食物摄入量略有增加,20%α-环糊精和20%乳糖组雄性动物的食物转化效率显著降低,但雌性动物未出现此情况。血液学参数未出现与治疗相关变化。与其他低消化性碳水化合物研究的类似观察结果一致,20%α-环糊精和20%乳糖组的尿液pH降低,尿钙水平升高。同样,这些组的粪便干重和氮输出增加。在治疗结束时,在5%和20%α-环糊精组以及20%乳糖组中观察到盲肠重量(充满和排空)显著增加。20%α-环糊精组雄性动物的脾脏相对(而非绝对)重量显著增加。在20%乳糖组中,脾脏和肝脏(雌性)以及睾丸、大脑和肾上腺(雄性)的相对重量显著增加。对这些以及所有其他器官和组织的组织病理学检查未发现可归因于α-环糊精或乳糖治疗的任何异常。总之,以高达20%的膳食水平摄入α-环糊精13周(分别相当于雄性和雌性大鼠每日摄入量为12.6和13.9 g/kg体重)未产生任何毒性迹象或不良反应。